$5.00
+0.10 (+2.04%)
Open$4.88
Previous Close$4.90
Day High$5.23
Day Low$4.88
52W High$57.14
52W Low$24.79
Volume—
Avg Volume246.7K
Market Cap42.04M
P/E Ratio57.94
EPS$0.67
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+808.4% upside
Current
$5.00
$5.00
Target
$45.42
$45.42
$30.66
$45.42 avg
$56.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.47M | 17.78M | 17.86M |
| Net Income | 823.9K | 633.2K | 616.7K |
| Profit Margin | 4.5% | 3.6% | 3.5% |
| EBITDA | 1.32M | 1.18M | 1.27M |
| Free Cash Flow | 745.4K | 469.0K | 453.6K |
| Rev Growth | +3.4% | -9.1% | -0.5% |
| Debt/Equity | 0.78 | 0.66 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |